Novo Nordisk reported DKK225.16B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Bausch Health Companies USD 4.53B 350M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novo Nordisk DKK 225.16B 9.5B Mar/2026
Novo Nordisk DKK 32.79B 203.33B Jun/2025
Pacira USD 108.79M 11.8M Mar/2026
Sanofi EUR 30.01B 1.66B Mar/2026
Supernus Pharmaceuticals USD 373.93M 35.76M Mar/2026